Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of STAT3

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6662-6672

  Fionda, Cinzia ^a   Malgarini, Giulia ^a   Soriani, Alessandra ^a   Zingoni, Alessandra ^a   Cecere, Francesca ^a   Iannitto, Maria Luisa ^a   Ricciardi, Maria Rosaria ^b   Federico, Vincenzo ^b   Petrucci, Maria Teresa ^b   Santoni, Angela ^a,c   Cippitelli, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Mediterranean Institute of Neuroscience   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DNAX ACCESSORY MOLECULE 1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; LYMPHOCYTE RECEPTOR; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DEGRANULATION; DOWN REGULATION; ENZYME INHIBITION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICA GENE; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84879115465     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201426     Document Type: Article

References (54)

1. Doble, B. W., and J. R. Woodgett. 2003. GSK-3: tricks of the trade for a multitasking kinase. J. Cell Sci. 116: 1175-1186. (Pubitemid 36410657)
2. Kockeritz, L., B. Doble, S. Patel, and J. R. Woodgett. 2006. Glycogen synthase kinase-3: an overview of an over-achieving protein kinase. Curr. Drug Targets 7: 1377-1388. (Pubitemid 44718298)
3. Wang, H., J. Brown, and M. Martin. 2011. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53: 130-140.
4. Cohen, P., and M. Goedert. 2004. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3: 479-487. (Pubitemid 38807530)
5. Beurel, E., S. M. Michalek, and R. S. Jope. 2010. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 31: 24-31.
6. Luo, J. 2009. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273: 194-200.
7. Kyle, R. A., and S. V. Rajkumar. 2008. Multiple myeloma. Blood 111: 2962-2972.
8. Mahindra, A., J. Laubach, N. Raje, N. Munshi, P. G. Richardson, and K. Anderson. 2012. Latest advances and current challenges in the treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 9: 135-143.
9. Mohty, B., J. El-Cheikh, I. Yakoub-Agha, H. Avet-Loiseau, P. Moreau, and M. Mohty. 2012. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia 26: 73-85.
10. Tricot, G., D. H. Vesole, S. Jagannath, J. Hilton, N. Munshi, and B. Barlogie. 1996. Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-1198. (Pubitemid 26043549)
11. Bruno, B., M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omedè, I. Baldi, et al. 2007. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 356: 1110-1120. (Pubitemid 46425595)
12. Frohn, C., M. Höppner, P. Schlenke, H. Kirchner, P. Koritke, and J. Luhm. 2002. Anti-myeloma activity of natural killer lymphocytes. Br. J. Haematol. 119: 660-664. (Pubitemid 35366205)
13. Hayashi, T., T. Hideshima, M. Akiyama, K. Podar, H. Yasui, N. Raje, S. Kumar, D. Chauhan, S. P. Treon, P. Richardson, and K. C. Anderson. 2005. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 128: 192-203.
14. Koh, C. Y., A. Raziuddin, L. A. Welniak, B. R. Blazar, M. Bennett, and W. J. Murphy. 2002. NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution. Biol. Blood Marrow Transplant. 8: 17-25. (Pubitemid 34141547)
15. Carbone, E., P. Neri, M. Mesuraca, M. T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, et al. 2005. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105: 251-258. (Pubitemid 40053090)
16. El-Sherbiny, Y. M., J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyler, S. J. Richards, F. E. Davies, et al. 2007. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cellmediated killing of myeloma cells. Cancer Res. 67: 8444-8449. (Pubitemid 47437416)
17. Jinushi, M., M. Vanneman, N. C. Munshi, Y. T. Tai, R. H. Prabhala, J. Ritz, D. Neuberg, K. C. Anderson, D. R. Carrasco, and G. Dranoff. 2008. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. USA 105: 1285-1290. (Pubitemid 351397045)
18. Girlanda, S., C. Fortis, D. Belloni, E. Ferrero, P. Ticozzi, C. Sciorati, M. Tresoldi, A. Vicari, T. Spies, V. Groh, et al. 2005. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res. 65: 7502-7508. (Pubitemid 41161286)
19. Soriani, A., A. Zingoni, C. Cerboni, M. L. Iannitto, M. R. Ricciardi, V. Di Gialleonardo, M. Cippitelli, C. Fionda, M. T. Petrucci, A. Guarini, et al. 2009. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113: 3503-3511.
20. Fionda, C., A. Soriani, G. Malgarini, M. L. Iannitto, A. Santoni, and M. Cippitelli. 2009. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J. Immunol. 183: 4385-4394.
21. Zhou, Y., S. Uddin, T. Zimmerman, J. A. Kang, J. Ulaszek, and A. Wickrema. 2008. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk. Lymphoma 49: 1945-1953.
22. Piazza, F., S. Manni, L. Q. Tubi, B. Montini, L. Pavan, A. Colpo, M. Gnoato, A. Cabrelle, F. Adami, R. Zambello, et al. 2010. Glycogen synthase kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer 10: 526.
23. Gunn, W. G., U. Krause, N. Lee, and C. A. Gregory. 2011. Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 117: 1641-1651.
24. Bedel, R., A. Thiery-Vuillemin, C. Grandclement, J. Balland, J. P. Remy-Martin, B. Kantelip, J. R. Pallandre, X. Pivot, C. Ferrand, P. Tiberghien, and C. Borg. 2011. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res. 71: 1615-1626.
25. Bryceson, Y. T., M. E. March, D. F. Barber, H. G. Ljunggren, and E. O. Long. 2005. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202: 1001-1012. (Pubitemid 41396899)
26. Mainiero, F., A. Soriani, R. Strippoli, J. Jacobelli, A. Gismondi, M. Piccoli, L. Frati, and A. Santoni. 2000. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity 12: 7-16. (Pubitemid 30069210)
27. Cippitelli, M., C. Fionda, D. Di Bona, F. Di Rosa, A. Lupo, M. Piccoli, L. Frati, and A. Santoni. 2002. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J. Immunol. 168: 1154-1166. (Pubitemid 34094480)
28. Dechow, T. N., L. Pedranzini, A. Leitch, K. Leslie, W. L. Gerald, I. Linkov, and J. F. Bromberg. 2004. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. USA 101: 10602-10607. (Pubitemid 38955788)
29. Yadav, D., J. Ngolab, R. S. Lim, S. Krishnamurthy, and J. D. Bui. 2009. Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J. Immunol. 182: 39-43.
30. He, B., Y. H. Meng, and N. F. Mivechi. 1998. Glycogen synthase kinase 3beta and extracellular signal-regulated kinase inactivate heat shock transcription factor 1 by facilitating the disappearance of transcriptionally active granules after heat shock. Mol. Cell. Biol. 18: 6624-6633. (Pubitemid 28500551)
31. Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner, and G. R. Crabtree. 1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275: 1930-1934.
32. Hoeflich, K. P., J. Luo, E. A. Rubie, M. S. Tsao, O. Jin, and J. R. Woodgett. 2000. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90. (Pubitemid 30460216)
33. Venkataraman, G. M., D. Suciu, V. Groh, J. M. Boss, and T. Spies. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 178: 961-969. (Pubitemid 46095169)
34. Rubinfeld, B., I. Albert, E. Porfiri, C. Fiol, S. Munemitsu, and P. Polakis. 1996. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026. (Pubitemid 26259322)
35. Littlewood, T. D., D. C. Hancock, P. S. Danielian, M. G. Parker, and G. I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23: 1686-1690.
36. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809.
37. Beurel, E., and R. S. Jope. 2008. Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 283: 21934-21944.
38. Song, H., R. Wang, S. Wang, and J. Lin. 2005. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 102: 4700-4705. (Pubitemid 40471517)
39. Beurel, E., and R. S. Jope. 2009. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J. Neuroinflammation 6: 9.
40. Beurel, E., and R. S. Jope. 2009. Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharide-induced IL-6 production in RAW264.7 cells. Cell. Signal. 21: 978-985.
41. Gasser, S. 2007. DNA damage response and development of targeted cancer treatments. Ann. Med. 39: 457-464. (Pubitemid 47479267)
42. Davies, F., and R. Baz. 2010. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 24(Suppl. 1): S13-S19.
43. Ullrich, E., M. Bonmort, G. Mignot, G. Kroemer, and L. Zitvogel. 2008. Tumor stress, cell death and the ensuing immune response. Cell Death Differ. 15: 21-28. (Pubitemid 350286169)
44. Zitvogel, L., L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer. 2008. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118: 1991-2001. (Pubitemid 351872317)
45. Armeanu, S., M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al. 2005. Natural killer cellmediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65: 6321-6329. (Pubitemid 40994418)
46. Wu, X., Y. Tao, J. Hou, X. Meng, and J. Shi. 2012. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia 14: 1178-1189.
47. Beurel, E., W. I. Yeh, S. M. Michalek, L. E. Harrington, and R. S. Jope. 2011. Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J. Immunol. 186: 1391-1398.
48. Aoukaty, A., and R. Tan. 2005. Role for glycogen synthase kinase-3 in NK cell cytotoxicity and X-linked lymphoproliferative disease. J. Immunol. 174: 4551-4558.
49. Alvarez, J. V., and D. A. Frank. 2004. Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol. Ther. 3: 1045-1050. (Pubitemid 41350982)
50. Calò, V., M. Migliavacca, V. Bazan, M. Macaluso, M. Buscemi, N. Gebbia, and A. Russo. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197: 157-168. (Pubitemid 37485244)
51. Catlett-Falcone, R., T. H. Landowski, M. M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J. L. Fernández-Luna, G. Nuñez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115. (Pubitemid 29077388)
52. Benson, D. M., Jr., C. E. Bakan, S. Zhang, S. M. Collins, J. Liang, S. Srivastava, C. C. Hofmeister, Y. Efebera, P. Andre, F. Romagne, et al. 2011. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118: 6387-6391.
53. de la Iglesia, N., G. Konopka, K. L. Lim, C. L. Nutt, J. F. Bromberg, D. A. Frank, P. S. Mischel, D. N. Louis, and A. Bonni. 2008. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J. Neurosci. 28: 5870-5878.
54. Niu, G., K. L. Wright, Y. Ma, G. M. Wright, M. Huang, R. Irby, J. Briggs, J. Karras, W. D. Cress, D. Pardoll, et al. 2005. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25: 7432-7440. (Pubitemid 41170107) Ricerca